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Primary tumor excision is one of the most widely used therapies of cancer. However, 
the risk of metastases development still exists following tumor resection. The liver is a 
common site of metastatic disease for numerous cancers. Breast cancer is one of the 
most frequent sources of metastases to the liver. The aim of this work was to evaluate the 
efficacy of the orally administered Salmonella Typhi vaccine strain CVD 915 on the devel-
opment of liver metastases in a mouse model of breast cancer. To this end, one group of 
BALB/c mice was orogastrically immunized with CVD 915, while another received PBS as 
a control. After 24 h, mice were injected with LM3 mammary adenocarcinoma cells into 
the spleen and subjected to splenectomy. This oral Salmonella-based vaccine produced 
an antitumor effect, leading to a decrease in the number and volume of liver metastases. 
Immunization with Salmonella induced an early cellular immune response in mice. This 
innate stimulation rendered a large production of IFN-γ by intrahepatic immune cells (IHIC) 
detected within 24 h. An antitumor adaptive immunity was found in the liver and celiac and 
portal lymph nodes (LDLN) 21 days after oral bacterial inoculation. The antitumor immune 
response inside the liver was associated with increased CD4+ and dendritic cell popu-
lations as well as with an inflammatory infiltrate located around liver metastatic nodules. 
Enlarged levels of inflammatory cytokines (IFN-γ and TNF) were also detected in IHIC. 
Furthermore, a tumor-specific production of IFN-γ and TNF as well as tumor-specific IFN-
γ-producing CD8 T cells (CD8+IFN-γ+) were found in the celiac and portal lymph nodes of 
Salmonella-treated mice. This study provides first evidence for the involvement of LDLN in 
the development of an efficient cellular immune response against hepatic tumors, which 
resulted in the elimination of liver metastases after oral Salmonella-based vaccination.
Keywords: Salmonella Typhi, vaccine, liver metastases, breast cancer, antitumor cD8+ T cells, Th1 immune 
response, celiac and portal lymph nodes
Abbreviations: DBW, differential body weight; IHIC, intrahepatic immune cells; LDLN, liver-draining lymph nodes; S. Typhi, 
Salmonella enterica serovar Typhi.
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inTrODUcTiOn
The development of novel cancer treatments is a major subject of 
study around the globe. More than 90% of cancer-related deaths 
are due to metastatic disease and not from the primary tumors 
from which they arise (1). Excision of primary tumors is one of 
the most widely used cancer treatments. However, the risk of 
metastases development still exists following tumor resection (2). 
Breast cancer is the most commonly diagnosed cancer and the 
second leading cause of cancer-related death in women world-
wide. Most deaths from breast cancer are from metastatic disease 
(3). The liver is a common site of metastatic disease for numerous 
types of cancer. Lung, colon, pancreatic, mammary, and gastric 
adenocarcinomas are the most frequent types of carcinoma to 
metastasize to the liver (4).
Cancer immunotherapy is increasingly acknowledged as an 
attractive therapeutic option and is now regarded as the fourth 
anti-cancer treatment (5). The ideal cancer immunotherapy 
should be tumor specific as well as effective for the residual 
or metastatic disease with minimal toxicity to normal cells. 
We have already demonstrated the efficacy of the Salmonella 
enterica serovar Typhi (S. Typhi)-attenuated vaccine strain 
CVD 915 as an immunotherapeutic agent in breast cancer (6) 
and T-cell lymphoma (7) mouse models. Significant tumor-
infiltrating TNF-producing neutrophils along with a decrease in 
intratumoral IL-10 levels and a reduction of regulatory T cells 
(Tregs) in draining lymph nodes were observed in both models. 
These events resulted in a delayed formation of metastases and 
increased survival times in both studies as well. Furthermore, 
we found a tumor-specific Th1 immune response in the draining 
lymph nodes of immunized animals in the mammary adenocar-
cinoma model. Remarkably, immunotherapy on the metastatic 
T-cell lymphoma stimulated a tumor-specific T-cell-mediated 
immunity, which resulted in complete tumor regression in 10% 
of the treated animals. A long-lasting antigen-specific immune 
response was induced in most of cured animals, as evidenced by 
the lack of tumor growth after a rechallenge with the homologous 
tumor. An additional relevant fact of our findings is that this S. 
Typhi strain is cytotoxic per se to murine T-cell lymphoma cells 
in vitro, but innocuous to normal splenocytes.
We have already reported that orogastrically (o.g.) inoculated 
CVD 915 proves to be a good adjuvant in a prophylactic cancer 
vaccine against a mouse T-cell lymphoma (8). Based on these find-
ings, we hypothesized that this neoadjuvant cancer therapy could 
act by activating the pre-existing immune system and breaking 
immune tolerance to cancer. According to this hypothesis, such 
an enhanced immune stimulation could promote the generation 
of effective antitumor responses, which inhibits the development 
of metastases and enhances the efficacy of the primary cancer 
therapy.
Despite the inherent tolerogenicity of the liver microenviro-
ment, which protects the organ from chronic inflammation 
due to intensive influx of antigens from intestinal bacteria (9), 
the liver is an immunocompetent organ. Indeed, intrahepatic 
immune cells (IHIC) produce the Th1-type cytokine IFN-γ after 
a bacterial challenge (10, 11). Our hypothesis suggests that oral 
administration of the bacterial strain may trigger a systemic 
proinflammatory immune response leading to a breakdown of 
the tolerogenic liver environment, thus favoring the detection 
and rejection of metastatic tumor cells in this organ by an innate 
immune response and a subsequent tumor-specific immune 
response. Accordingly, the main goal of this work was to assess 
the effectiveness of a bacterial-based vaccine on the develop-
ment of liver metastases in a mouse model of breast cancer. We 
demonstrated that the orally administered S. Typhi CVD 915 
promotes an efficient antitumor immune response that results in 
a decrease in hepatic metastases. Moreover, we found that the 
recently identified main liver-draining celiac and portal lymph 
nodes (12, 13) are involved in the immune response against both 
Salmonella and hepatic tumors.
MaTerials anD MeThODs
cells and culture conditions
LM3 is a murine mammary adenocarcinoma cell line syngeneic to 
BALB/c mice. It was established by Urtreger et al. (14) and kindly 
provided by Dr. Elisa Bal de Kier Joffé (Research Area, Institute of 
Oncology Angel H. Roffo, Buenos Aires). Cells derived from pas-
sages 58–66 were used throughout this study and were cultured, 
as previously described (6).
Intrahepatic immune cells, mesenteric lymph nodes (MLN), 
and liver-draining lymph nodes (LDLN) cells obtained from 
BALB/c mice were cultured at 37°C in a humidified 5% CO2 
environment in RPMI supplemented with 2  mM glutamine, 
25 mM HEPES, 0.05 mM 2-mercaptoethanol, 100 U/ml penicil-
lin, 100 μg/ml streptomycin, and 10% heat-inactivated fetal calf 
serum (FCS).
Bacterial strain
Salmonella Typhi CVD 915 was kindly provided by Dr. Myron 
Levine (Center for Vaccine Development, University of Maryland 
School of Medicine, Baltimore, MD, USA). This vaccine strain 
(15) is a ΔguaBA mutant from S. Typhi strain Ty2. Bacteria were 
routinely cultured and prepared for inoculation, as previously 
described (6).
Mice
Eight- to twelve-week-old BALB/c female mice were purchased 
from the School of Veterinary Sciences, University of Buenos 
Aires, Argentina. All mice were maintained in an enriched envi-
ronment and in accordance with institutional animal care and use 
guidelines. Ethics committee for the care and use of laboratory 
animals [Comité institucional de cuidado y uso de animales de 
laboratorio (CICUAL), Facultad de Medicina, UBA] approved the 
research protocol. Distress and suffering were avoided as much as 
possible. All procedures were carried out by a veterinarian.
Treatment and liver Metastases Tumor 
Model
Healthy mice were first treated with 50 μl of 10% sodium bicar-
bonate by o.g. gavage for gastric acid neutralization. After 15 min, 
they received 200 μl CVD 915 bacterial suspension in sterile PBS 
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(1 ×  109 CFU) or PBS alone as a control, also via o.g. Twenty-
four hours later, animals were challenged with LM3 tumor cells, 
using the liver metastases tumor model designed by Lafreniere 
and Rosenberg (16). Briefly, mice were anesthetized with a com-
bination of Ketamine (100 mg/kg) and Xylazine (10 mg/kg) by 
intraperitoneal (i.p.) injection. The spleen was inoculated with 
1 ×  105 LM3 tumor cells through a left subcostal incision, and 
splenectomy was performed three min later. Animals were housed 
for 3 weeks until metastases were macroscopically visible. Twenty-
four hours or 21 days after treatment animals were sacrificed for 
sampling. A veterinarian routinely monitored sudden deaths and 
clinical signs of discomfort or illness in all mice throughout the 
experiments, such as weight loss, apathy, trembling, restricted 
motility, vomits, diarrhea, rash, and swelling.
Mice were weighted before treatment and at sacrifice. For sam-
pling, they were anesthetized with Ketamine/Xylazine (i.p.) and 
bled by heart puncture with a heparinized syringe. Livers were 
perfused with cold PBS via the portal vein and then removed, 
weighted, and processed for the isolation of IHIC. Spleen, MLN, 
and/or LDLN (portal and celiac nodes) were removed and disag-
gregated into a single-cell suspension. Celiac and portal lymph 
nodes were identified anatomically as described by Zheng et al. 
(13) and sampled.
Hepatic metastases were measured and quantified using a stereo 
zoom microscope (loupe) (4×) (16). The hepatic tumor volume was 
calculated as the sum of the volumes of all nodules, which were 
estimated using the two-dimensional mathematical formula for 
ellipsoidal tumors: V = π/6 × f × (length × width)3/2 (17).
The liver metastases model used has an effectiveness of ~88% 
and does not allow discrimination between mice that failed to 
develop metastases from those eventually cured by the treat-
ment. Thus, only those animals showing macroscopically visible 
metastases 20 days after the challenge were included in further 
analysis.
Quantification of Salmonella in liver
Balb/c mice were treated with CVD 915 via o.g. route, as described 
previously. One, four, eight, or twenty-four hours after the bacte-
rial inoculation, mice were euthanized and livers aseptically 
removed and homogenized in distilled water. Samples of homog-
enized livers were seeded in agar plates for CFU determination, 
as previously described (6).
intrahepatic immune cell isolation
Intrahepatic immune cells were isolated by mechanical disrup-
tion followed by Percoll density separation as described by Blom 
et al. (18), with minor modifications. Briefly, livers were disag-
gregated through a nylon cell strainer, using a syringe plunger, 
and then suspended in 50 ml of RPMI 10% FCS. This suspension 
was centrifuged at 60 × g for 1 min at room temperature without 
brake. The resulting supernatant was centrifuged at 480  ×  g 
with brake for 8 min at room temperature. The pellet obtained 
was resuspended in 5  ml of Percoll 33% in PBS with heparin 
(100 U/ml) and centrifuged at 850 × g for an additional 30 min 
at room temperature without brake. The resulting pellet, con-
taining the IHIC and contaminant erythrocytes, was subjected 
to hypoosmotic lysis and then washed with complete medium. 
Cells were then resuspended in complete medium for cell surface 
phenotyping by flow cytometry or functional analysis.
immunofluorescence staining and Flow 
cytometric analysis
Blood, spleen, MLN, LDLN, and IHIC were assayed for pheno-
typic analysis by immunofluorescence and flow cytometry, using 
rat monoclonal antibodies against mouse leukocyte antigens, 
as follows: PE anti-CD8, FITC anti-CD4, PE anti-B220, PE 
anti-CD11c, biotin anti-CD49, PE anti-Ly-6G (Gr1), and biotin 
anti-MHC II (eBioscience, San Diego, CA, USA). APC- or 
PE-conjugated streptavidin and isotype-matched controls were 
used as required. Immunofluorescence surface staining and flow 
cytometric analysis were performed, as previously described 
(6). The neutrophil population was defined as that expressing 
the highest level of Gr1 and gated as shown in Figure S1 in 
Supplementary Material. The dendritic cell (DC) subset was 
defined as that expressing CD11c gated as shown in Figure S1 in 
Supplementary Material. Lymphocytes were gated as shown in 
Figure S1 in Supplementary Material.
IFN-γ-production by tumor-specific CD8+ T cells was 
measured by intracellular staining, as previously described (6). 
IHIC and LDLN cells, obtained from mice after 20 days of tumor 
challenge, were cultured for 96 h in the presence or absence of 
LM3 cells (at a ratio 10:1). Thereafter, cells were activated for 
4 h with PMA (20 ng/ml) and ionomycin (500 ng/ml, both from 
Sigma, St. Louis, MO, USA) in the presence of 2 μg/ml Brefeldin 
A (BFA, eBioscience), and then labeled with fluorescent antibod-
ies, as previously described. Samples were processed using a BD 
FACSCalibur or a BD Accuri C6 flow cytometer (BD Biosciences, 
San Jose, CA, USA). Multicolor flow cytometric analysis was 
performed using the Flowing Software 2.5.1 (Perttu Thero, Turku, 
Finland).
Measurement of cytokines by elisa
Intrahepatic immune cells and LDLN cells (0.5 × 106 and 1 × 106/
well, respectively) obtained from treated and control mice were 
cultured separately in 96-well plates in the presence or absence of 
LM3 tumor cells at a 10:1 ratio. Supernatants were collected 72- or 
96-h later, and cytokines (IFN-γ, TNF, and IL-2) were measured 
by ELISA (eBioscience) following the manufacturer’s instruc-
tions. The detection limits were 30, 4, and 4 pg/ml, respectively.
histopathological analysis
Twenty-one days after treatment, S. Typhi-treated and control 
mice were euthanized. Livers were removed and fixed with 10% 
buffered formalin before paraffin embedding. Hematoxylin and 
eosin (H&E) staining of paraffin-embedded sections was per-
formed, as previously described (19). Organs were examined for 
the presence of metastases and leukocyte infiltrates.
statistical analysis
All data are shown as mean ± SEM. For comparisons between 
groups, unpaired Student’s t-test was used. For comparisons 
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between more than two groups, an ANOVA followed by a 
post-ANOVA Tukey’s multiple comparison test was performed. 
When data were not normally distributed, the Mann–Whitney 
test was used for comparison between two groups. Differences 
were considered significant when p < 0.05 for all comparisons. 
The statistical analysis was performed using Prism 5.0 software 
(GraphPad, La Jolla, CA, USA).
resUlTs
Oral S. Typhi Does not colonize Mouse 
liver
Orally delivered attenuated Salmonella Typhimurium has been 
shown to infect mouse liver (20). However, there have been no 
studies investigating liver colonization by attenuated S. Typhi 
strains. In mice inoculated orally with S. Typhi vaccine strain 
CVD 915, we found no vaccine organisms in liver tissue removed 
1, 4, 8, and 24 h post vaccination.
Oral Vaccination with cVD 915 in naive 
Mice induces an early immune response 
in the liver and lDln
To determine whether oral immunization with S. Typhi could 
elicit an efficient immune response in the mouse liver, we inocu-
lated orally naive mice with 109 CFU of CVD 915. Twenty-four 
hours later, mice were sacrificed and blood, spleen, liver, and 
LDLN were analyzed.
We found an increased frequency of circulating CD4+ T cells 
and a decreased population of B220+ B cells from Salmonella-
immunized mice as compared with PBS-inoculated control 
ones (Figure 1A). Furthermore, enhanced frequencies of innate 
immune cells, NK (CD49+) and neutrophils (Gr1+), were detected 
in the spleen (Figures 1B,C, respectively).
We next assessed the involvement of the main LDLN in the 
immune response after oral immunization with Salmonella. 
The frequency of CD4+ T cells was enhanced at the expense of 
decreased B220+ B cells in LDLN from Salmonella-immunized 
mice with respect to control ones (Figure  1D). Moreover, the 
percentage of DC (CD11c+) was also increased in treated mice as 
compared with control animals (Figure 1E).
The phenotypic analysis of IHIC populations from treated 
mice did not reveal any variations in the proportion of CD4+, 
CD8+, B220+, or CD49+ lymphocytes as compared with control 
mice, as shown in Figure  1F. However, the measurement of 
cytokine production by IHIC revealed a significant difference 
between both groups. IHIC were cultured ex vivo for 72  h 
without additional stimulation. Then, cytokines synthesized by 
these cells were measured in the culture supernatant by ELISA 
(Figure 1G). An increase in IFN-γ levels produced by the IHIC 
of more than 10-fold was detected in Salmonella-treated mice, 
as compared with control animals, whereas no differences 
were found in TNF levels. This result indicates a strong innate 
IFN-γ production in the liver, which is triggered by the oral-
administered Salmonella.
Taken together, these results confirm that the oral vaccination 
with CVD 915 was capable of inducing a systemic (in blood and 
spleen) and local (in liver and LDLN) innate immune response.
Oral Salmonella-Based immunotherapy 
reduces the hepatic lM3 Tumor Burden 
and Proves to Be Well Tolerated
To assess the incidence of liver metastases following oral vaccina-
tion with CVD 915, mice were orally immunized with Salmonella 
or PBS. Twenty-four hours later, LM3 tumor cells were inoculated 
using the liver metastases mouse model explained above. The 
prophylactic efficacy of bacterial administration on the develop-
ment of liver metastases was evaluated 20 days later, by count-
ing and measuring liver tumor nodules. A significant decrease 
in the hepatic tumor burden was found in Salmonella-treated 
mice (Figure  2A). Indeed, livers from treated animals showed 
a 50% reduction in the number of tumor nodules (Figure 2B) 
and a 45% decrease in tumor volume, as compared with PBS-
treated mice (Figure 2C). Furthermore, livers from non-treated 
animals were ~15% heavier than those from Salmonella-treated 
ones (mean ± SEM) (1.43 ± 0.10 vs. 1.22 ± 0.06 g, respectively; 
p = 0.04), indicating that oral Salmonella promotes tumor mass 
reduction. These results show a strong therapeutic efficacy of this 
bacteria-based vaccine in preventing the development of liver 
metastases.
Reduction in body weight gain is a sensitive indicator of 
toxicity in rodent studies (21). In order to assess safety and toler-
ability of the oral treatment with Salmonella, tumor-challenged 
and naive animals were weighted, before and after treatment, 
and side effects were monitored. Mice from all groups gained 
almost 2 g in 3 weeks. There was no disparity in body weights 
between control and treated mice, either inoculated or not with 
LM3 cells (Figure  2D). Furthermore, no adverse effects were 
noted during the experiment and all animals appeared to be 
healthy upon clinical observation. These data suggest that oral 
Salmonella-based vaccine was well tolerated both in naive and 
tumor-bearing animals.
Oral Salmonella achieves an antitumor 
Therapeutic effect by Triggering a  
cell-Mediated immune response in the 
liver and lDln
Twenty-one days after treatment, the liver, MLN, and LDLN 
were removed and leukocyte populations from the organs were 
characterized. The phenotypic analysis of MLN populations from 
treated mice did not reveal any differences in the percentages of 
CD4+, CD8+ or B220+ lymphocytes as compared with control 
mice (p >  0.05), as shown in Figure  3A. This result indicated 
that MLN are not involved in the antitumor cellular immune 
response against liver metastases generated after oral Salmonella-
based treatment. We next examined whether the liver and 
LDLN are involved in the immune mechanism underlying the 
antitumoral effects of this oral vaccine. An increased frequency 
of CD4+ T cells at the expense of decreased B cells (B220+) was 
FigUre 1 | early immune response with iFn-γ production in liver of naive mice after oral Salmonella administration. BALB/c mice were immunized with 
CVD 915 via o.g. or PBS as a control. After 24 h, animals were sacrificed for sampling. (a–F) Cell phenotype of individual mice was analyzed by flow cytometry 
(n = 3–13). (a) Percentage of blood cells. (B) Percentage of splenic lymphocytes. (c) Percentage of splenic neutrophils. (D) Percentage of lymphocytes from 
liver-draining lymph nodes (LDLN). (a–D) *p < 0.05; ns, not statistically significant. Data are from one experiment representative of three to five. (e) Percentage of 
CD11c+ cells between LDLN cells, gated on DC region as defined in Section “Materials and Methods.” *p < 0.05. (F) Percentage of lymphocytes from intrahepatic 
immune cells (IHIC). ns, not statistically significant. (e,F) Data are from three experiments. (g) IFN-γ and TNF levels produced by IHIC measured by ELISA. The limits 
of detection were 30 and 4 pg/ml, respectively. ***p < 0.001; ns = not statistically significant (n = 9). Data are from two experiments.
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detected in CVD 915-treated mice when compared to controls 
(Figure 3B). Interestingly, a similar pattern was found in IHIC, 
with an increased frequency of CD4+ T cells and a decrease in the 
B220+ cell population (Figure 3C). No significant differences in 
the frequencies of CD8+ T cells were found between both groups 
of mice. In addition, the percentages of CD11c+ and MHC 
FigUre 2 | anti-metastatic effects of the oral Salmonella vaccine  
cVD 915. Twenty-one days after treatment with CVD 915 or PBS, livers from 
tumor-bearing mice were removed. (a) Representative images of one liver 
from each group are shown. Arrows indicate a representative tumor nodule 
(B) Number of superficial tumor nodules per liver. (c) Liver tumor volumes. 
(B,c) Dots represent the tumor number or volume of each mouse. *p < 0.05, 
**p < 0.01 (n = 8–9). Data are from two experiments representative of four. 
(D) Body weight gain of naive and tumor-challenged mice. Mice were weighed 
before (day 0) and 21 days after treatment. Box and whiskers represent the 
differential body weight (DBW) of each group. ns, not statistically significant 
(n = 3–5). Data are from one experiment representative of three.
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(Figure  3E). These results indicate that oral Salmonella-based 
vaccine promotes an antitumor cell-mediated immune response 
in the liver and LDLN.
Oral Salmonella induces an antitumor 
Th1-Type cellular immune response in 
the liver and lDln
Immune analysis was performed 21  days after immunization. 
Primary cultures from IHIC or LDLN cells were exposed (or not) 
to LM3 cells. Then, levels of IL-2, TNF, and IFN-γ were deter-
mined in culture supernatants. In cultures unexposed to tumor 
cells, enhanced levels of these three cytokines were found in IHIC 
and LDLN cultures from Salmonella-treated mice, as compared 
with those from control PBS-treated mice (Figures 4A–C). When 
LDLN cells from Salmonella-treated mice were exposed to tumor 
cells, the levels of IFN-γ and TNF increased, whereas the levels 
of IL-2 decreased with respect to the unexposed culture from the 
same group (Figures 4A–C). When IHIC from bacterial-treated 
animals were cultured with tumor cells, the level of TNF enlarged, 
whereas the concentration of IL-2 decreased with respect to the 
unexposed culture from the same group. Nevertheless, IFN-γ 
levels generated by IHIC from bacteria-treated animals did not 
increase in the presence of LM3 cells (Figure 4A). These results 
suggest that a tumor-specific Th1-type immune response is 
elicited in the liver and its associated draining lymph nodes in 
Salmonella-treated mice.
Oral Salmonella elicits Tumor-specific 
cD8+iFn-γ+ effector T cells in lDln
After a 96-h coculture of LDLN cells from PBS- or Salmonella-
treated mice with (or without) LM3 tumor cells, immune cells 
were immunocharacterized and stained for intracytoplasmic 
IFN-γ. An enlarged percentage of CD8+IFN-γ+ T-cells was found 
in LDLN from bacteria-treated mice that had been cultured with 
tumor cells, as compared with non-treated controls (Figure 5). 
Interestingly, in the Salmonella-treated group, the IFN-γ produc-
tion by CD8 T cells was higher after incubation with LM3 tumor 
cells. Representative dot plots showing percentage of CD8+IFN-γ+ 
T-cells are available in the Figure S2 in Supplementary Material. 
These results indicate that oral immunization with Salmonella 
stimulates a tumor-specific immune response that is capable of 
generating effector CD8+ T cells in LDLN.
Oral Salmonella-Based immunotherapy 
induces leukocytic infiltration in the liver, 
Mainly around Metastatic nodules
A comprehensive histopathologic analysis of livers from tumor-
bearing mice 21  days after treatment was performed. CVD 
915-treated mice exhibited livers with large leukocyte infiltration, 
including lymphocytes, monocytes, and neutrophils surround-
ing tumor nodules. In contrast, a poor infiltrate was seen in only 
some untreated livers (Figures  6A,B). Livers from Salmonella-
treated mice were highly infiltrated by leukocytes in the perivas-
cular tissue (Figure 6C), whereas most control livers exhibited 
poorly infiltrated. These results complement flow cytometric 
II+ expressing-cells were increased in the liver (Figure  3D). 
Moreover, DC (CD11c+ cells) from treated-mice expressed 
higher levels of MHC II molecules than DC from controls 
FigUre 3 | enhance cellular immune response in the liver and lnDn after cancer treatment with oral Salmonella. Twenty-one days after treatment with 
CVD 915 or PBS, livers, mesenteric lymph nodes (MLN) and liver draining lymph nodes (LDLN) from tumor-bearing mice were analyzed by flow cytometry.  
(a) Percentages of CD4+, CD8+, and B220+ lymphocytes from MLN. (B) Percentages of CD4+, CD8+, and B220+ lymphocytes from LDLN. (c) Percentages of 
CD4+, CD8+, and B220+ lymphocytes from intrahepatic immune cells (IHIC). (D) Percentages of CD11c+ and MHC II+ cells between the IHIC. (e) Representative 
histograms showing expression of MHC class II on gated CD11c+ DC from IHIC. Bar graph represents the median fluorescence intensity (MFI) of MHC II expression 
on CD11c+ cells. (a–D) ns, not statistically significant, *p < 0.05, ***p < 0.0001. All data shown are mean values of three pooled samples from four to five animals 
per group and are representative of one to four experiments.
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immunophenotype data, providing additional information about 
the location of the leukocytic infiltrate induced by Salmonella.
DiscUssiOn
One of the promising strategies in cancer immunotherapy 
is to use the power of the efficient immune response against 
microbial agents to fight malignancy. The liver is a particular 
immunological site in which tolerance mechanisms prevail over 
an immune-reactive state (9). Thus, breaking the hepatic toler-
ance and counteracting the immunosuppressive mechanisms 
induced by cancer cells within the liver are required to induce an 
effective immune response against liver cancer. In this study, we 
demonstrate the ability of the CVD 915 Salmonella-based vac-
cine to reduce the development of liver metastases from breast 
cancer cells by promoting a substantial reduction of the overall 
hepatic tumor burden in Salmonella-treated mice. This result is 
in agreement with preliminary studies from our group showing 
that this treatment can elicit similar therapeutic response against 
hepatic metastases in a mouse model of liver metastases from 
T-cell lymphoma (data not shown). The liver is a common target 
of cancer metastases. The fact that Salmonella-based vaccines 
prove to be useful against breast and lymphoma metastases 
implies that they might be suitable to treat metastases from other 
FigUre 5 | Tumor-specific iFn-γ-producing cD8+ cells in liver-
draining lymph nodes (lDln) after oral Salmonella-based treatment. 
Twenty-one days after treatment with CVD 915 or PBS, LDLN from 
tumor-bearing mice were removed. Samples from three animals per group 
were pooled. LDLN cells were stimulated or not with LM3 tumor cells for 
96 h. Then, CD8+ surface expression and intracellular IFN-γ production were 
measured by flow cytometry as indicated in Section “Materials and Methods.” 
Bars represent the mean ± SEM percentage of CD8+IFN-γ+ T cells per 
culture of LDLN cells. **p < 0.01 (n = 6–10).
FigUre 4 | antitumor Th1-type cytokine production in the liver and 
liver-draining lymph nodes (lDln) from Salmonella-treated mice. 
Twenty-one days after treatment with CVD 915 or PBS, livers and LDLN from 
tumor-bearing mice were removed. Cytokine production was measured by 
ELISA in 96 h culture supernatants of intrahepatic immune cells (IHIC) and 
LDLN cells following exposure to LM3 tumor or not. (a) IFN-γ, (B) TNF, and 
(c) IL-2. The limits of detection were 30, 4, and 4 pg/ml, respectively. 
Samples from four to five animals per group were pooled. Data shown are 
mean values of triplicate or quadruplicate cultures and are representative of 
two independent experiments. ns, not statistically significant, *p < 0.05, 
**p < 0.001, ***p < 0.0001.
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types of cancer. Our findings correlate with other studies in 
which orally attenuated Salmonella Typhimurium was tested in 
a mouse model of liver metastases from colon adenocarcinoma 
(22, 23). Based on our results, orally attenuated Salmonella-based 
vaccination could be used in patients as a neoadjuvant therapy 
before the resection of the primary tumor, especially to prevent 
the development of liver metastases. It could be also speculated 
that the use of human-restricted, attenuated strains of S. Typhi 
should be more appropriate to achieve a wider dissemination 
throughout the body, thus favoring tumor colonization by 
bacteria in humans. Future clinical trials in cancer patients might 
prove this hypothesis.
Previous reports have proposed the resection of liver metas-
tases from breast cancer in order to improve survival in patients 
with solitary liver metastases (24). In addition, it was noted that 
the numbers and sizes of liver tumor nodules are crucial fac-
tors for success in this therapy (25). The significant reduction 
in the number and volume of liver metastases achieved with 
Salmonella-based immunization, although not curative, might 
enhance patient survival and increase the chances of success after 
liver surgery.
Unlike humans, mice are resistant to oral infection with S. 
Typhi (26, 27). Because CVD 915 is an auxotrophic strain of S. 
Typhi, it should be less capable of in vivo multiplication in the 
mouse than a wild-type strain (28). This issue could explain 
the absence of liver colonization by the attenuated strain CVD 
915. Salmonella antigens could spread to the liver via the portal 
vein like those from the intestinal bacterial flora (11). DCs in 
the gastrointestinal tissue have a unique morphology, which is 
characterized by extended transepithelial dendrites. These pro-
cesses allow DC to sample antigens directly from the lumen (29) 
and drive them to the liver. Liver DC circulate through hepatic 
sinusoids toward lymph draining vessels and undergo an increase 
in expression levels of MHC II molecules and IL-12 upon matura-
tion (30). It could be also hypothesized that antigen-loaded DC 
and/or exosomes from bacterial-infected macrophages recruited 
into the liver after treatment, act as antigen presenting cells to 
prime specific T cells in the liver and/or LDLN (31, 32).
FigUre 6 | liver-infiltrating inflammatory cells after oral Salmonella-based treatment. Twenty-one days after treatment, livers were removed from 
tumor-bearing mice. Images showing representative H&E stained liver sections from CVD 915- (left panels) or PBS-treated (right panels) animals. (a,B) Image of a 
metastatic focus in the liver. (a) Original magnification 400×. (B) Original magnification 100×. (c) Left: image of perivascular infiltrating leukocytes. Right: absence of 
perivascular infiltrate (original magnification 1000×). (a–c) Images shown are from one liver representative of five animals per group. (1) tumor nodule, (2) hepatic 
tissue, black arrows indicate leukocyte infiltration around a metastatic nodule, white arrows indicate the absence of leukocyte infiltration around a metastatic nodule.
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Several authors have already studied the immunogenicity of 
live S. Typhi vaccines administered by mucosal routes in mouse 
models (33–35), especially humoral or cellular immune responses 
in blood and spleen. However, the immune response to these vac-
cine strains in the liver and its main draining lymph nodes (celiac 
and portal nodes) has not been documented so far. In this study, 
we demonstrate that a strain of S. Typhi provokes a strong innate 
immune response in the liver, which is characterized by a huge 
increase in the IFN-γ production by IHIC and augmented DC 
and CD4+ T cell populations in celiac and portal LDLN. Other 
authors have demonstrated that mice infected with Salmonella 
Typhimurium develop a Th1 response characterized by the 
production of large amount of IFN-γ, mainly by the IHIC (36). 
Further, Zhang et al. identified hepatic NK cells as the principal 
IFN-γ-expressing lymphocyte upon acute E. coli challenge (10), 
although NKT and conventional T cells were also involved in 
IFN-γ production. Thus, NK is probably the most important 
source of IFN-γ in the liver of Salmonella-treated mice. Further 
studies should be performed in order to elucidate the role of these 
cell populations as early effectors of innate immunity activated 
by Salmonella in our liver metastases model. Collectively, our 
findings provide first evidence for an involvement of the liver-
draining celiac and portal lymph nodes in the hepatic immune 
response against oral Salmonella spp.
Although humoral immunity is desirable for acute infections, 
antitumor Th1-type cellular immunity is responsible for eradicating 
established cancers (37). We detected an increased frequency in the 
CD4+ cell population and a decrease in the B220+ cell population 
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(mostly B cells) both in LDLN and liver from treated mice. These 
results are consistent with a predominant T-cell-mediated immune 
response located at the tumor site and LDLN. Besides, it is broadly 
known that IFN-γ is a critical component of the immune system 
in antitumor immune responses (38). Here, we demonstrated a 
huge increase in production of Th1-type cytokines (including 
IFN-γ, TNF, and IL-2) by IHIC and LDLN cells in Salmonella-
treated animals. Moreover, IFN-γ and TNF levels produced by 
LDLN increased in the presence of LM3 cells, thus indicating a 
tumor-specific cellular immune response. Furthermore, a tumor-
specific TNF production by IHIC was found in immunized mice. 
By contrast, IL-2 levels decreased upon in vitro tumor-stimulation 
of lymphoid cells from Salmonella-treated mice. The decline of 
IL-2 levels could be due, at least in part, to its consumption by 
antigen-induced IL-2α receptor+ (CD25+) cells, such as activated 
tumor-specific CD4- and CD8-T lymphocytes (39). Since IFN-γ 
and TNF exert synergic cytotoxic effects on endothelial and tumor 
cells (40), the presence of these Th1-type cytokines in the liver 
microenvironment, the tumor site, could significantly contribute 
to the antitumor effects promoted by oral Salmonella-based 
immunotherapy. However, we cannot rule out the involvement 
of Th2- and/or Th17-type cytokines in the antitumoral immunity 
induced by oral Salmonella-based vaccination.
The IFN-γ expression by CD8+ cells is a reliable functional 
surrogate for the identification of cytotoxic T lymphocytes (41). 
Herein, we demonstrate an increased percentage of tumor-spe-
cific CD8+IFN-γ+ T cells in the LDLN from Salmonella-treated 
mice. These data show that oral Salmonella-based vaccination 
breaks liver immunosuppression, thus favoring the development 
of a tumor-specific immune response in LDLN and, probably, 
the migration of effector CD8+IFN-γ+ T cells toward the liver. 
It can be also noted that a higher leukocytic infiltrate surround-
ing liver tumor nodules was found in Salmonella-treated mice, 
which suggests a positive response to therapy (42). Evidence 
from clinical studies indicates that Tregs have well-defined roles 
in suppressing antitumor immunity [i.e., through a negative 
feedback on effector T cells (43)]. Also, Tregs are important in 
maintaining liver immunological self tolerance (44). Based on 
these data and our previous findings demonstrating that CVD 
915-based immunotherapy reduce Tregs in tumor-draining 
lymph nodes in mice (6, 7), it can be speculated that this oral 
Salmonella-based vaccination will also be able to promote a 
decrease in the Treg cell population in the liver and/or LDLN, 
thus supporting the generation of an efficient tumor-specific 
cellular immunity.
Lymph nodes have a key role in host defense against pathogens 
and also, tumors. This study provides new insight into the critical 
role of main liver-draining lymph nodes (celiac and portal nodes) 
in the cellular immune response against hepatic tumors, which 
resulted in the elimination of liver metastases in LM3 tumor-
bearing mice after oral Salmonella-based vaccination. In contrast, 
MLN nodes appeared to play a secondary role. These results agree 
with previous data from Barbier et al. (12). These authors dem-
onstrated that celiac and portal nodes are the preferential site of 
DC migration and T cell activation in mice. However, they rarely 
detected the activation of T cells in the first mesenteric node. 
Interestingly, our findings will further provide valuable insights 
for understanding the immune response to hepatic tumors and 
for performing appropriate preclinical validation of new anti-
liver cancer therapies, including immunotherapies.
In conclusion, this study demonstrates that an oral live 
attenuated S. Typhi vaccine strain can elicit a successful immune 
response, which is capable of preventing the development of liver 
metastases. The early type-1 innate immunity activated by a single 
oral dose of a S. Typhi is sufficient to break not only liver-inherent 
immune tolerance but also tumor-induced immunosuppression. 
The proinflammatory microenvironment elicited in the liver 
by oral Salmonella triggers a tumor-specific Th1-type immune 
response, which efficiently reaches the liver and its recently 
identified draining lymph nodes rendering a drastic reduction 
of hepatic metastases. The proven antitumor efficacy of oral S. 
Typhi vaccination encourages future clinical evaluation of this 
simple and inexpensive immunotherapy as a neoadjuvant and/or 
adjuvant treatment for liver metastatic cancer.
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